TOP > 外国特許検索 > PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER

PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER UPDATE

外国特許コード F180009655
整理番号 3995
掲載日 2018年11月21日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP054893
国際公開番号 WO 2014133085
国際出願日 平成26年2月27日(2014.2.27)
国際公開日 平成26年9月4日(2014.9.4)
優先権データ
  • 特願2013-037426 (2013.2.27) JP
発明の名称 (英語) PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER UPDATE
発明の概要(英語) Abacavir, which is a nucleoside analogue reverse transcriptase inhibitor, has been found to exhibit anti-cancer activity with respect to ATL cells in vitro, without hindering the DNA replication of normal cells. Abacavir, or a pharmacologically acceptable derivative thereof, is effective as an active ingredient of pharmaceutical compositions for the prevention and/or treatment of cancer, and in particular breast cancer and cancers having abnormalities in the DNA repair mechanism, such as adult T-cell leukemia.
従来技術、競合技術の概要(英語) BACKGROUND ART
Nucleoside reverse transcriptase inhibitors (NRTI: Nucleoside Analogue Reverse Transcriptase Inhibitor) is, anti-human immunodeficiency virus type 1 (hereinafter 'HIV-1' hereinafter) has been developed as a drug, an anti-HIV treatment current nuclei are used as a medicament. However, with respect to zidovudine (AZT) from its prototype, as well as the reverse transcription of the virus, can also induce DNA replication of normal cells has been known (see non-patent document 1). On the other hand, the same human retrovirus HIV-1 human T-cell leukemia virus type 1 (hereinafter 'HTLV-1' hereinafter) with respect to, various types of nucleic acid-based reverse transcriptase inhibitor antiviral effect in or to be known. Further, due to the infection HTLV-1 (Adult T cell Leukemia adult T-cell leukemia, hereinafter referred to as' ATL ') in the treatment of combination therapy with zidovudine and interferon (IFN) is performed, then the effect is reported (non-patent document 2, reference 3). However, in the in vitro anti-cancer effect to the cell that ATL zidovudine is reported that it is not (see non-patent document 4) and, the mechanism of action of zidovudine ATL cells that is unknown in many cases.
Which is a kind of NRTI abacavir (ABC) is in clinical use as an anti-HIV and, also has an effect of anti-HTLV-1 have been reported (see non-patent document 5). However, anti-cancer effect of abacavir has not been known.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • TAKAORI, Akifumi
  • TAKEDA, Shunichi
  • KOBAYASHI, Masayuki
  • TADA, Kohei
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close